CIRM Chairman on Geron: Agency in for the Long Haul
Commenting on Geron's decision to abandon hESC research, the chairman of the California stem cell agency, Jonathan Thomas, says the agency knew "the road to new therapies would be arduous, and that for each success, there would be setbacks as well."
In a memo Monday to the agency's 29 board members, Thomas reiterated that Geron maintains the decision had…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.